Emerging Companies

Mycovia tackling chronic infections with antifungal pipeline

Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections. The company's lead product VT-1161 otesaconazole is in Phase III testing for...

Arkuda emerges from Atlas with genetic dementia program

Atlas-founded Arkuda is developing compounds for frontotemporal dementia due to genetic lysosomal deficits that could be applied to other neurodegenerative diseases linked to lysosomal dysfunction. Arkuda Therapeutics Inc. debuted Thursday with a $44 million series...

Ervaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter of the...

Tmunity: Manufacturing momentum for CAR and TCR therapies

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors. Andreessen Horowitz (a16z) led...

Disc Medicine: Seeking Iron Balance via Hepcidin

Disc debuted Tuesday with a $50 million series A round and a pair of hepcidin modulators aimed at carving a place in hematological disorders, alongside a host of disease-modifying therapies that are much closer to...

Deep Genomics: Letting AI take the wheel

Deep Genomics announced its first candidate in September, pulling back the curtain on its holistic AI-enabled discovery platform that is designed to identify viable antisense oligonucleotide candidates faster than traditional discovery methods. CEO Brendan Frey...

Intrepida: Tackling the innate immune system to treat cancer

With a $9.5 million equity round, Intrepida aims to begin clinical testing by early 2021 of its first-in-class mAbs against BAG3, which can modulate the innate immune response to inhibit tumor growth in pancreatic cancer....

Verseau unveils tumor macrophage reprogramming strategy

Verseau is aiming to treat solid tumor patients who don't respond to T cell-targeting agents by reprogramming tumor-associated macrophages to make them immuno-stimulatory. Eight months after announcing a collaboration with 3SBio Inc. (HKSE:1530), Verseau Therapeutics...

Inscopix: scoping out better preclinical models via live brain imaging

With a platform to perform in vivo brain imaging, Inscopix Inc. is aiming to fix the poor predictive power of preclinical animal models for CNS diseases. Its advantage is the ability to use changes in...

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...

AI play Healx raises $56M to repurpose drugs for rare disease

Bolstered by a $56 million series B round, Healx is taking human bias out of drug discovery by leaving most strategic and technical decisions up to AI. Its approach is to use an AI-powered platform...

Abalos’ arena: planning to upstage oncolytic viruses

Abalos launched Tuesday with a €12 million ($13.2 million) series A round to advance its arenavirus-based cancer therapies, which offer an alternative to oncolytic viruses, and rely on prolonged immune responses to clear tumors. Boehringer...

Flagship unveils Cygnal, a nervy take on cancer, inflammation

Cygnal Therapeutics Inc. believes overlooked corners of neurobiology could unlock therapeutic strategies in cancer, inflammation and beyond. With $65 million from Flagship Pioneering and other undisclosed investors, the company launched Tuesday to advance two candidates...

Gene editing vets launch Korro to convert RNA bases

A trio of gene editing industry veterans have teamed up to launch Korro Bio as their second company developing antisense-based therapies in less than a year. Korro is creating a new CRISPR-independent version of RNA...

Icosavax’s self-assembling vaccine platform

Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its...